AAPL   318.72 (+0.15%)
MSFT   182.09 (+0.38%)
FB   225.04 (-0.19%)
GOOGL   1,420.98 (+0.19%)
AMZN   2,407.50 (+0.27%)
NVDA   344.09 (+1.36%)
CGC   17.58 (-19.06%)
BABA   198.81 (-0.35%)
TSLA   819.16 (+1.66%)
AMD   52.28 (+1.04%)
T   30.48 (-1.87%)
DIS   115.19 (-1.34%)
NFLX   413.35 (-0.02%)
BAC   24.38 (-1.93%)
AAPL   318.72 (+0.15%)
MSFT   182.09 (+0.38%)
FB   225.04 (-0.19%)
GOOGL   1,420.98 (+0.19%)
AMZN   2,407.50 (+0.27%)
NVDA   344.09 (+1.36%)
CGC   17.58 (-19.06%)
BABA   198.81 (-0.35%)
TSLA   819.16 (+1.66%)
AMD   52.28 (+1.04%)
T   30.48 (-1.87%)
DIS   115.19 (-1.34%)
NFLX   413.35 (-0.02%)
BAC   24.38 (-1.93%)
AAPL   318.72 (+0.15%)
MSFT   182.09 (+0.38%)
FB   225.04 (-0.19%)
GOOGL   1,420.98 (+0.19%)
AMZN   2,407.50 (+0.27%)
NVDA   344.09 (+1.36%)
CGC   17.58 (-19.06%)
BABA   198.81 (-0.35%)
TSLA   819.16 (+1.66%)
AMD   52.28 (+1.04%)
T   30.48 (-1.87%)
DIS   115.19 (-1.34%)
NFLX   413.35 (-0.02%)
BAC   24.38 (-1.93%)
AAPL   318.72 (+0.15%)
MSFT   182.09 (+0.38%)
FB   225.04 (-0.19%)
GOOGL   1,420.98 (+0.19%)
AMZN   2,407.50 (+0.27%)
NVDA   344.09 (+1.36%)
CGC   17.58 (-19.06%)
BABA   198.81 (-0.35%)
TSLA   819.16 (+1.66%)
AMD   52.28 (+1.04%)
T   30.48 (-1.87%)
DIS   115.19 (-1.34%)
NFLX   413.35 (-0.02%)
BAC   24.38 (-1.93%)
Log in

NASDAQ:SYRSSyros Pharmaceuticals Stock Price, Forecast & News

$9.57
+0.06 (+0.63 %)
(As of 05/29/2020 02:07 PM ET)
Add
Compare
Today's Range
$9.23
Now: $9.57
$9.68
50-Day Range
$6.97
MA: $8.80
$10.18
52-Week Range
$4.26
Now: $9.57
$11.93
Volume23,984 shs
Average Volume360,464 shs
Market Capitalization$437.25 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. It has target discovery, research collaboration, and option agreement with Incyte to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co., Ltd. for the development and commercialization of SY-1425. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Read More
Syros Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYRS
CUSIPN/A
Phone617-744-1340

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.98 million
Book Value$1.68 per share

Profitability

Net Income$-75,440,000.00
Net Margins-1,950.42%

Miscellaneous

Employees76
Market Cap$437.25 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

How has Syros Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYRS shares have increased by 85.8% and is now trading at $9.57. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Syros Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Syros Pharmaceuticals.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Syros Pharmaceuticals.

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals Inc (NASDAQ:SYRS) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.39) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.06. The business had revenue of $2.38 million for the quarter, compared to the consensus estimate of $1.72 million. Syros Pharmaceuticals had a negative net margin of 1,950.42% and a negative return on equity of 84.15%. View Syros Pharmaceuticals' earnings history.

What price target have analysts set for SYRS?

6 equities research analysts have issued twelve-month price targets for Syros Pharmaceuticals' stock. Their forecasts range from $8.00 to $18.00. On average, they expect Syros Pharmaceuticals' stock price to reach $13.17 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price. View analysts' price targets for Syros Pharmaceuticals.

Has Syros Pharmaceuticals been receiving favorable news coverage?

News stories about SYRS stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a news impact score of 1.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the next several days. View the latest news aboutSyros Pharmaceuticals.

Are investors shorting Syros Pharmaceuticals?

Syros Pharmaceuticals saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 2,830,000 shares, an increase of 19.4% from the April 15th total of 2,370,000 shares. Based on an average trading volume of 248,100 shares, the days-to-cover ratio is presently 11.4 days. Approximately 8.8% of the company's stock are short sold. View Syros Pharmaceuticals' Current Options Chain.

Who are some of Syros Pharmaceuticals' key competitors?

What other stocks do shareholders of Syros Pharmaceuticals own?

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the following people:
  • Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)
  • Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)
  • Dr. David A. Roth, Chief Medical Officer (Age 56)
  • Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)
  • Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (10.78%), Nikko Asset Management Americas Inc. (11.35%), Sumitomo Mitsui Trust Holdings Inc. (11.35%), Arch Venture Corp (6.71%), BlackRock Inc. (6.16%) and JPMorgan Chase & Co. (1.93%). Company insiders that own Syros Pharmaceuticals stock include Jeremy P Springhorn, Mark J Alles, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch. View institutional ownership trends for Syros Pharmaceuticals.

Which major investors are selling Syros Pharmaceuticals stock?

SYRS stock was sold by a variety of institutional investors in the last quarter, including Arch Venture Corp, JPMorgan Chase & Co., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., BlackRock Inc., Morgan Stanley, and Squarepoint Ops LLC. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Richard A Young, and Venture Fund Vii LP Arch. View insider buying and selling activity for Syros Pharmaceuticals.

Which major investors are buying Syros Pharmaceuticals stock?

SYRS stock was acquired by a variety of institutional investors in the last quarter, including Portolan Capital Management LLC, Invesco Ltd., Los Angeles Capital Management & Equity Research Inc., Geode Capital Management LLC, AlpInvest Partners B.V., AQR Capital Management LLC, SG Americas Securities LLC, and Alliancebernstein L.P.. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn, Mark J Alles, and Srinivas Akkaraju. View insider buying and selling activity for Syros Pharmaceuticals.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $9.57.

How big of a company is Syros Pharmaceuticals?

Syros Pharmaceuticals has a market capitalization of $437.25 million and generates $1.98 million in revenue each year. The company earns $-75,440,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is www.syros.com.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.